Sangamo Therapeutics(SGMOQ)
$0.11-0.01 (-7.69%)
SGMOQ
Sangamo Therapeutics financials statements
$0.11
At close:-0.01 (-7.69%)
Want to see SGMOQ full AI Analyst Report?
Sangamo Therapeutics (SGMOQ) Ratios
2,675 Followers
Sangamo Therapeutics Ratios
SGMOQ's free cash flow for Q1 2026 was $-19.30M. For the 2026 fiscal year, SGMOQ's free cash flow was decreased by $-13.00K and operating cash flow was $-19.28M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.84 | 1.13 | 1.98 | 2.69 | 3.12 |
| Quick Ratio | 0.84 | 1.13 | 1.98 | 2.69 | 3.12 |
| Cash Ratio | 0.49 | 0.92 | 0.95 | 0.90 | 1.40 |
| Solvency Ratio | -1.56 | -1.12 | -2.86 | -0.67 | -0.46 |
| Operating Cash Flow Ratio | -2.29 | -1.47 | -4.71 | -2.00 | -1.82 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -38.18M | $ -27.17M | $ 11.89M | $ 32.78M | $ 52.19M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.45 | 0.30 | 0.23 | 0.08 | 0.07 |
| Debt-to-Equity Ratio | -1.88 | 1.34 | 0.46 | 0.15 | 0.13 |
| Debt-to-Capital Ratio | 2.14 | 0.57 | 0.31 | 0.13 | 0.11 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -4.19 | 4.46 | 1.99 | 1.91 | 1.92 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.10 | 0.15 | 0.22 | 0.28 | 0.33 |
| Net Debt to EBITDA | -0.05 | 0.13 | 0.07 | 0.30 | 0.79 |
| Profitability Margins | |||||
| Gross Profit Margin | 80.78% | 100.00% | 100.00% | 89.12% | 100.00% |
| EBIT Margin | -312.25% | -170.33% | -67.52% | -180.85% | -165.61% |
| EBITDA Margin | -293.03% | -154.13% | -54.93% | -169.97% | -149.68% |
| Operating Profit Margin | -273.07% | -179.88% | -155.48% | -180.85% | -165.61% |
| Pretax Profit Margin | -312.25% | -169.74% | -149.18% | -172.37% | -160.79% |
| Net Profit Margin | -310.81% | -169.45% | -146.30% | -172.76% | -161.05% |
| Continuous Operations Profit Margin | -310.81% | -169.45% | -146.30% | -172.76% | -161.06% |
| Net Income Per EBT | 99.54% | 99.83% | 98.07% | 100.22% | 100.17% |
| EBT Per EBIT | 114.35% | 94.36% | 95.95% | 95.31% | 97.08% |
| Return on Assets (ROA) | -205.76% | -96.37% | -155.96% | -34.18% | -24.70% |
| Return on Equity (ROE) | 861.59% | -430.13% | -311.06% | -65.19% | -47.50% |
| Return on Capital Employed (ROCE) | -625.06% | -186.22% | -233.02% | -44.65% | -30.86% |
| Return on Invested Capital (ROIC) | -566.39% | -172.58% | -219.94% | -44.25% | -30.66% |
| Return on Tangible Assets | -205.76% | -96.37% | -155.96% | -40.55% | -28.37% |
| Earnings Yield | -104.46% | -47.61% | -272.04% | -39.67% | -16.44% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.76 | 12.57 | 43.33 | 24.89 | 17.40 |
| Payables Turnover | 0.53 | 0.00 | 0.00 | 0.54 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.80 | 1.66 | 3.33 | 0.89 | 0.89 |
| Asset Turnover | 0.66 | 0.57 | 1.07 | 0.20 | 0.15 |
| Working Capital Turnover Ratio | -105.47 | 2.20 | 1.50 | 0.48 | 0.28 |
| Cash Conversion Cycle | -596.16 | 29.04 | 8.42 | -661.13 | 20.98 |
| Days of Sales Outstanding | 97.02 | 29.04 | 8.42 | 14.67 | 20.98 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 693.17 | 0.00 | 0.00 | 675.80 | 0.00 |
| Operating Cycle | 97.02 | 29.04 | 8.42 | 14.67 | 20.98 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.35 | -0.33 | -1.29 | -1.45 | -1.61 |
| Free Cash Flow Per Share | -0.35 | -0.33 | -1.41 | -1.58 | -1.77 |
| Dividend Paid and CapEx Coverage Ratio | -953.02 | -251.46 | -10.63 | -11.09 | -10.02 |
| Capital Expenditure Coverage Ratio | -953.02 | -251.46 | -10.63 | -11.09 | -10.02 |
| Operating Cash Flow Coverage Ratio | -3.63 | -2.20 | -5.90 | -5.19 | -4.85 |
| Operating Cash Flow to Sales Ratio | -2.46 | -1.16 | -1.28 | -2.01 | -2.11 |
| Free Cash Flow Yield | -82.69% | -32.76% | -259.56% | -50.30% | -23.66% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.95 | -2.08 | -0.37 | -2.52 | -6.08 |
| Price-to-Sales (P/S) Ratio | 2.98 | 3.56 | 0.54 | 4.35 | 9.79 |
| Price-to-Book (P/B) Ratio | -8.25 | 9.04 | 1.14 | 1.64 | 2.89 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.21 | -3.05 | -0.39 | -1.99 | -4.23 |
| Price-to-Operating Cash Flow Ratio | -1.21 | -3.06 | -0.42 | -2.17 | -4.65 |
| Price-to-Earnings Growth (PEG) Ratio | 0.09 | 0.03 | -0.02 | -1.55 | -0.17 |
| Enterprise Value Multiple | -1.07 | -2.18 | -0.91 | -2.26 | -5.75 |
| Enterprise Value | 123.53M | 194.38M | 87.68M | 427.31M | 953.47M |
| EV to EBITDA | -1.07 | -2.18 | -0.91 | -2.26 | -5.75 |
| EV to Sales | 3.12 | 3.36 | 0.50 | 3.84 | 8.61 |
| EV to Free Cash Flow | -1.27 | -2.88 | -0.36 | -1.75 | -3.72 |
| EV to Operating Cash Flow | -1.27 | -2.90 | -0.39 | -1.91 | -4.09 |
| Tangible Book Value Per Share | -0.05 | 0.11 | 0.48 | 1.34 | 1.95 |
| Shareholders’ Equity Per Share | -0.05 | 0.11 | 0.48 | 1.91 | 2.60 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.02 | -0.00 | -0.00 |
| Revenue Per Share | 0.14 | 0.29 | 1.01 | 0.72 | 0.77 |
| Net Income Per Share | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 |
| Tax Burden | 1.00 | 1.00 | 0.98 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 2.21 | 0.95 | 0.97 |
| Research & Development to Revenue | 2.85 | 1.93 | 1.33 | 2.25 | 2.09 |
| SG&A to Revenue | 0.88 | 0.77 | 0.35 | 0.56 | 0.57 |
| Stock-Based Compensation to Revenue | 0.23 | 0.21 | 0.16 | 0.28 | 0.30 |
| Income Quality | 0.79 | 0.69 | 0.87 | 1.16 | 1.31 |
Currency in USD

